These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9354660)

  • 1. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies.
    Iuliano L; Praticò D; Ferro D; Pittoni V; Valesini G; Lawson J; FitzGerald GA; Violi F
    Blood; 1997 Nov; 90(10):3931-5. PubMed ID: 9354660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies.
    Martinuzzo ME; Forastiero RR; Kordich L; Carreras LO
    Br J Haematol; 2001 Sep; 114(4):845-51. PubMed ID: 11564073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation.
    Praticò D; Ferro D; Iuliano L; Rokach J; Conti F; Valesini G; FitzGerald GA; Violi F
    Blood; 1999 May; 93(10):3401-7. PubMed ID: 10233892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IPF2alpha-I: an index of lipid peroxidation in humans.
    Praticò D; Barry OP; Lawson JA; Adiyaman M; Hwang SW; Khanapure SP; Iuliano L; Rokach J; FitzGerald GA
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3449-54. PubMed ID: 9520386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome?
    Ghirardello A; Doria A; Ruffatti A; Rigoli AM; Vesco P; Calligaro A; Gambari PF
    Ann Rheum Dis; 1994 Feb; 53(2):140-2. PubMed ID: 8129460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for looking at the antiphospholipid antibodies in systemic lupus erythematosus.
    Stratta P; Canavese C; Ferrero S; Grill A; Piccoli G
    Nephron; 1997; 76(4):400-5. PubMed ID: 9274836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of antibodies to beta2-glycoprotein 1 from patients with systemic lupus erythematosus.
    Cabral AR; Cabiedes J; Alarcón-Segovia D
    Lupus; 2004; 13(3):182-7. PubMed ID: 15119547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL).
    Savelli SL; Roubey RAS; Kitzmiller KJ; Zhou D; Nagaraja HN; Mulvihill E; Barbar-Smiley F; Ardoin SP; Wu YL; Yu CY
    Front Immunol; 2019; 10():885. PubMed ID: 31134052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients.
    Tarr T; Lakos G; Bhattoa HP; Shoenfeld Y; Szegedi G; Kiss E
    Lupus; 2007; 16(1):39-45. PubMed ID: 17283584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological manifestations of systemic lupus erythematosus: role of antiphospholipid antibodies.
    Golstein M; Meyer O; Bourgeois P; Palazzo E; Nicaise P; Labarre C; Kahn MF
    Clin Exp Rheumatol; 1993; 11(4):373-9. PubMed ID: 8403581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and clinical significance of antiphospholipid antibodies to noncardiolipin antigens in systemic lupus erythematosus.
    Toschi V; Motta A; Castelli C; Gibelli S; Cimminiello C; Molaro GL; Gibelli A
    Haemostasis; 1993; 23(5):275-83. PubMed ID: 8175049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study.
    Chen J; Sun S; Yan Q; Bao C; Fu Q
    Clin Rheumatol; 2016 Feb; 35(2):333-40. PubMed ID: 26753544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placental pathology in systemic lupus erythematosus with antiphospholipid antibodies.
    Ogishima D; Matsumoto T; Nakamura Y; Yoshida K; Kuwabara Y
    Pathol Int; 2000 Mar; 50(3):224-9. PubMed ID: 10792786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
    İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
    Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
    Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
    Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased formation of the isoprostanes IPF2alpha-I and 8-epi-prostaglandin F2alpha in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans.
    Reilly MP; Delanty N; Roy L; Rokach J; Callaghan PO; Crean P; Lawson JA; FitzGerald GA
    Circulation; 1997 Nov; 96(10):3314-20. PubMed ID: 9396422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis.
    Moroni G; Ventura D; Riva P; Panzeri P; Quaglini S; Banfi G; Simonini P; Bader R; Meroni PL; Ponticelli C
    Am J Kidney Dis; 2004 Jan; 43(1):28-36. PubMed ID: 14712424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus.
    Martini F; Farsi A; Gori AM; Boddi M; Fedi S; Domeneghetti MP; Passaleva A; Prisco D; Abbate R
    Lupus; 1996 Jun; 5(3):206-11. PubMed ID: 8803891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual.
    Frodlund M; Vikerfors A; Grosso G; Skogh T; Wetterö J; Elvin K; Gunnarsson I; Kastbom A; Dahlström Ö; Rönnelid J; Svenungsson E; Sjöwall C
    Clin Exp Immunol; 2018 Oct; 194(1):27-38. PubMed ID: 30208508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment.
    Ferro D; Saliola M; Meroni PL; Valesini G; Caroselli C; Praticò D; Fitzgerald GA; Shoenfeld Y; Violi F
    J Thromb Haemost; 2003 Mar; 1(3):523-31. PubMed ID: 12871461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.